Compare Abeona Therapeutics Inc (ABEO) vs Bank of Nova Scotia (BNS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Bank of Nova Scotia — how do they compare? Abeona Therapeutics Inc trades at $7.37 (market cap $421.19M), while Bank of Nova Scotia trades at $89.87 (market cap $108.32B). The key difference: Bank of Nova Scotia is far larger — about 257.2× Abeona Therapeutics Inc's market cap, and Bank of Nova Scotia pays a 3.64% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | BNS | |
|---|---|---|
Market Cap | $421.19M | $108.32B |
Sector | Health | Financials |
52-Week High | $7.45 | $90.29 |
52-Week Low | $4.17 | $56.41 |
Enterprise Value | $276.10M | — |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
Bank of Nova Scotia (BNS) trades at $88.56, down 0.33% on the day. The stock exhibits a bullish technical trend with strong analyst support, evidenced by a 'Buy' consensus from 53% of covering analysts. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $1.47 surpassing the $1.42 estimate. The company maintains a solid net income margin of 24.86% and recently announced a dividend of $1.14 per share, highlighting its commitment to shareholder returns.
The outlook for BNS is positive, supported by earnings momentum, a diversified banking model, and an attractive dividend. Key risks include exposure to macroeconomic volatility and competitive pressures in the banking sector. The current valuation, with a P/E of 17.1, appears reasonable relative to its profitability and growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →
